tarcocimab tedromer
Tarcocimab tedromer is an anti-VEGF therapy developed by Kodiak Sciences using a novel antibody-biopolymer conjugate platform designed to extend the duration of action in retinal disease and reduce the frequency of intravitreal injections. The active antibody inhibits VEGF — the driver of abnormal retinal blood vessel growth in wet AMD and diabetic macular edema — while the biopolymer prolongs retention in the eye toward a 6-month dosing interval. Standard anti-VEGF drugs require injections every 1–3 months; tarcocimab has missed primary endpoints in two prior Phase 3 programs and is in a new pivotal trial for wet AMD versus aflibercept.
Upcoming catalysts
Programs
Wet AMD
Wet AMD is the leading cause of severe vision loss in adults over 50, driven by VEGF-stimulated abnormal retinal blood vessel growth; standard anti-VEGF injections must be repeated every 1–3 months indefinitely, creating a substantial burden on patients and retina clinics. After missing endpoints in two prior Phase 3 trials in different indications, this pivotal program tests tarcocimab in wet AMD, asking whether Kodiak's biopolymer platform can achieve BCVA non-inferiority to aflibercept while supporting extended dosing intervals.